Healthcare Equipment and Supplies
Company Overview of Xenios AG
Xenios AG develops medical devices for the treatment of acute and chronic lung failure. The company offers iLA active, a platform that provides the spectrum of solutions for pumped extrapulmonary lung support; iLA activve kits; NovaTherm Heater/Cooler that allows targeted therapeutic tempering of the patient’s blood; iLA Membrane Ventilator for pumpless (arterio-venous) extrapulmonary lung support; and NovaFlow c Ultrasonic Flowcomputer for blood flow measurements. It also provides NovaPort twin double lumen cannulas for veno-venous vascular access; NovaPort one cannulas for cardiac and pulmonary support, as well as for perioperative perfusion for less invasive cardiac/aortic surgery; deltas...
Im Zukunftspark 1
Founded in 2013
Key Executives for Xenios AG
Vice President of Finance & Information Technology
Vice President of Operations
Managing Director and Chief Marketing & Medical Officer
Vice President of Research & Development
Compensation as of Fiscal Year 2016.
Xenios AG Key Developments
Xenios AG Enrolls First Patient in “Syncor” Clinical Trial of its CE-Marked i-cor® Device to Treat Cardiogenic Shock
Mar 29 16
Xenios AG announced that the first patient has been enrolled in the “SynCor” clinical trial of its CE-marked i-cor® Synchronized Cardiac Assist System for treating cardiogenic shock. The SynCor trial is a prospective, non-randomized, multi-center, open-label observational study of the safety and performance of the i-cor System in 45 consecutively enrolled patients with cardiogenic shock or in high-risk percutaneous intervention procedures in the cardiac catheterization lab. Synchronized Cardiac Assist “overlays” or “superimposes” a physiological pulse wave onto the patient’s weakened pulse and is designed to be a less-invasive treatment than the current standard while using a more physiological treatment essential to endothelial function, which ensures adequate tissue perfusion in the organs. Maintaining organ function serves to prevent multi-organ failure and to improve clinical outcomes. The oxygenating power of the i-cor Synchronized Cardiac System allows for a reduction of invasiveness compared to standard care by reducing blood flow and thus reducing cannula size. As a result, i-cor is designed to offer physiological circulatory support, protection, and safety during interventions in the cardiac cath lab, as well as for the management of cardiogenic shock in the ICU and the cardiac cath lab. The i-cor® system is a small extracorporeal pump that is synchronized to the heart beat (the ECG) so that augmentation of cardiac output with well-oxygenated blood occurs during diastole. The i-cor system, which provides Synchronized Cardiac Assist, combines the best elements of cardiac assist and augmented cardiac function associated with IABP and percutaneous ventricular assist devices but does not increase left ventricular afterload or ventricular work. The i-cor® Synchronized Cardiac Assist device reduces the mechanical and energy required by the heart to generate adequate blood pressure and blood flow to perfuse the tissues of each organ. The purpose of the SynCor trial is to study the safety and performance of the i-cor® Synchronized Cardiac Assist device in order to optimize the performance of device in the setting of cardiogenic shock following or associated with cardiac ischemic events, as well as in the setting of high-risk percutaneous intervention procedures in the cardiac catheterization lab.
Study Demonstrates i-COR Synchronized Cardiac Assist Preserves Left Ventricular Function Compared to Continuous-Flow ECLS in Cardiogenic Shock
Dec 10 15
XENiOS announced that its i-COR Synchronized Cardiac Assist System protects left ventricular (LV) function compared to continuous-flow ECLS (extracorporeal life support) in cardiogenic shock. Study data were presented at the recent American Heart Association (AHA) annual meeting in Orlando, Fla., by principal investigator PetrOštádal, M.D., Ph.D., Charles University, Na Homolce Hospital, Prague, Czech Republic. In the Oštádal study, myocardial hypoxia resulted in a decline in mean (±SD) cardiac output to 2.3±1.2 L/min, systolic blood pressure to 61±7 mmHg and LV ejection fraction (EF) to 21±7%. Synchronized pulsatile flow was associated with significant reduction of LV end-systolic volume (ESV), increase in LV stroke volume (SV), and higher EF at all ECLS flow levels compared to continuous ECLS flow. At selected ECLS flow levels, pulsatile flow reduced also LV end-diastolic pressure (EDP), end-diastolic volume (EDV), and systolic pressure (SP). Patients with cardiogenic shock have a very high mortality rate. Cardiogenic shock is a medical emergency. Cardiogenic shock results from an inadequate circulation of blood due to primary failure of the heart ventricles to function effectively. As this is a type of circulatory shock, there is insufficient perfusion of tissue. The condition involves increasingly more pervasive cell death from oxygen starvation (hypoxia). Synchronized Cardiac Assist “overlays” or “superimposes” a physiological pulse wave onto the patient’s weakened pulse and is designed to be a less invasive treatment than the current standard while using a more physiological treatment designed to be essential to endothelial function, which ensures adequate tissue perfusion in the organs. Maintaining organ function serves to prevent multi-organ failure and to improve clinical outcomes. The energy of synchronized pulsatility in conjunction with the i-cor Synchronized Cardiac Assist device allows for a reduction of invasiveness compared to standard care by reducing blood flow and thus reducing cannula size. As a result, i-cor is designed to offer physiological cardiac assist, protection, and safety during interventions in the cardiac cath lab, as well as for the management of cardiogenic shock in the ICU and the cardiac cath lab.
Xenios AG Expands Manufacturing and R&D Operations
Dec 1 15
XENIOS AG announced that it has expanded its operations to include its rapidly grown R&D group and an integrated larger manufacturing capacity as the company continues its aggressive growth strategy. The new XENIOS combined-manufacturing-and-R&D facility is located in Reutlingen, just 30+ miles (50 km) south of corporate headquarters in Heilbronn, in a regional cluster of universities, hospitals and biomedical research facilities that have a strong focus on medical device technology, basic science and engineering.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 28, 2016
September 21, 2016
|XOR Labs Inc.